Brief: Oncolytics Biotech Presents Clinical Proof-Of-Concept Data In Multiple Myeloma At The ASCO Virtual Annual Meeting
29/05/2020 12:25
May 29 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PRESENTS CLINICAL PROOF-OF-CONCEPT
DATA IN
MULTIPLE MYELOMA AT THE ASCO VIRTUAL ANNUAL MEETING
* ONCOLYTICS BIOTECH INC - COMBINATION THERAPY WITH
PELAREOREP
ACTIVATES A PROFOUND INFLAMMATORY RESPONSE
* ONCOLYTICS BIOTECH - 50% OVERALL RESPONSE RATE, 83%
CLINICAL
BENEFIT RATE IN PATIENTS WHO FAILED CARFILZOMIB
Source text for Eikon: ID:nPn1PlXdqa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer